PTC
TVRD

Private Trust Company’s Tvardi Therapeutics TVRD Stock Holding History

Private Trust Company’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$255 – 2449
2023
Q3 		$255 Hold
4
– – ﹤0.01% 2272
2023
Q2 		$430 Hold
4
– – ﹤0.01% 2223
2023
Q1 		$746 Sell
4
-2
-33% -$670 ﹤0.01% 2179
2022
Q4 		$2K Sell
6
-1
-14% -$380 ﹤0.01% 2059
2022
Q3 		$2K Buy
+7
New +$2.54K ﹤0.01% 1919

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Private Trust Company's TVRD Position: Q4 2023 in Review

Private Trust Company sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 4 shares — an estimated $255 sold.

Private Trust Company first reported a position in TVRD in Q3 2022 and held it in 5 quarters. The position peaked at $2K in Q4 2022. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • Private Trust Company reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Private Trust Company sold 4 Tvardi Therapeutics shares in Q4 2023, an estimated $255.
  • Private Trust Company first reported a position in Tvardi Therapeutics in Q3 2022 and held it in 5 quarters.
  • Private Trust Company's Tvardi Therapeutics position peaked at $2K in Q4 2022.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Private Trust Company's 13F filing for Q4 2023, filed 24 Jan 2024.